Immuneering IMRX
NASDAQ IMRX
$4.10 +0.01 (+0.12%)
As of: Oct 1, 2026 · 2:29 PM EDT

Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)

Updated

Immuneering (IMRX) reported Preferred Stock Liabilities of $82.89 million for Q2 2021, up 292.5% from $21.12 million a year earlier and up 42.7% from the prior quarter.

Analysis

Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Immuneering posted Preferred Stock Liabilities of $58.1 million.

  • Per Business Quant data, the three quarters before Q2 2021 came in at $58.1 million (Q1 2021), $58.1 million (Q4 2020) and $21.12 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Immuneering 264.61 Mn 264.61 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 82.89 Mn
Mar 31, 2021 58.10 Mn
Dec 31, 2020 58.10 Mn
Sep 30, 2020 21.12 Mn
Jun 30, 2020 21.12 Mn
API Access

Immuneering Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=IMRX&period=max&api_key=YOUR_API_KEY